European Journal of Paediatric Neurology 2012-07-01

Acute and chronic corticosteroid treatment of ten patients with paralytic form of Sydenham's chorea.

Carlo Fusco, Valentina Ucchino, Daniele Frattini, Francesco Pisani, Elvio Della Giustina

Index: Eur. J. Paediatr. Neurol. 16(4) , 373-8, (2012)

Full Text: HTML

Abstract

To determine efficacy and safety of corticosteroid treatment in patients with severe Sydenham's chorea paralytic form.This is a 4 years observational study on ten patient with severe paralytic form of Sydenham's chorea unresponsive to neuroleptics and antiepileptics agents, treated with intravenous methylprednisolone followed by oral deflazacort therapy. Chorea paralytica patients were bedridden, unable to take independent steps, showed severe generalized hypotonia and were hospitalized for 3-4 weeks. Additional clinical evaluations were undertaken at 1, 3 and 6 months and 1, 2 and 4 years from onset of chorea. Severity chorea at the onset and during follow up was rated according to Universidade Federal de Minas Gerais (UFMG) Sydenham's Chorea Rating Scale (USCRS). In all children video-recording was performing at onset and during clinical follow-up.We reported a significant improvement in swallowing and chewing with partial recovery of language 2-3 days after starting intravenous methylprednisolone treatment and complete disappearance of movement disorders after 3-4 weeks of treatment. All our patients were followed for 4 years from onset and none experienced relapse of chorea, other movement disorders or psychiatric disturbances. The treatment with deflazacort was well-tolerated in all children with no significant side effects reported.Our data showed that high dose of methylprednisolone intravenously followed by deflazacort therapy may be effective and well-tolerated in children with severe paralytic form of Sydenham's chorea.Copyright © 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.


Related Compounds

Related Articles:

Health-related quality of life in children and adolescents with Duchenne muscular dystrophy.

2012-12-01

[Pediatrics 130(6) , e1559-66, (2012)]

Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.

2012-06-01

[Muscle Nerve 45(6) , 796-802, (2012)]

Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial.

2013-01-01

[Orphanet J. Rare Dis. 8 , 26, (2013)]

Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases.

2000-04-01

[J. Oral. Pathol. Med. 29(4) , 145-52, (2000)]

Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.

2012-12-01

[Neuromuscul. Disord. 22(12) , 1046-56, (2012)]

More Articles...